摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,5-二甲基噻唑-4-乙酸 | 306937-38-2

中文名称
2,5-二甲基噻唑-4-乙酸
中文别名
2-(2,5-二甲基-1,3-噻唑)-4-乙酸;2-(2,5-二甲基-1,3-噻唑-4-基)乙酸;2-(2,5-二甲基噻唑-4-基)乙酸
英文名称
2-(2,5-dimethyl-1,3-thiazol-4-yl)acetic acid
英文别名
2-(2,5-dimethyl-4-thiazolyl)acetic acid;(2,5-dimethyl-1,3-thiazol-4-yl)acetic acid;(2,5-dimethyl-thiazol-4-yl)-acetic acid;2-(2,5-Dimethylthiazol-4-yl)acetic acid
2,5-二甲基噻唑-4-乙酸化学式
CAS
306937-38-2
化学式
C7H9NO2S
mdl
MFCD02677725
分子量
171.22
InChiKey
FFPWICPYXBDRHM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    110 °C
  • 沸点:
    320.5±27.0 °C(Predicted)
  • 密度:
    1.295±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    11
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.428
  • 拓扑面积:
    78.4
  • 氢给体数:
    1
  • 氢受体数:
    4

安全信息

  • 危险品标志:
    Xi
  • 安全说明:
    S26,S37/39
  • 危险类别码:
    R36/37/38
  • 海关编码:
    2934100090
  • 危险性防范说明:
    P261,P302+P352,P304+P340,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:ed25fb431cfe48708203585ba96a9dcf
查看
Name: 2-(2 5-Dimethyl-1 3-thiazol-4-yl)acetic acid 97% Material Safety Data Sheet
Synonym:
CAS: 306937-38-2
Section 1 - Chemical Product MSDS Name:2-(2 5-Dimethyl-1 3-thiazol-4-yl)acetic acid 97% Material Safety Data Sheet
Synonym:

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
306937-38-2 2-(2,5-Dimethyl-1,3-thiazol-4-yl)aceti 97% unlisted
Hazard Symbols: XI
Risk Phrases: 36/37/38

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 306937-38-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: brown
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 98 - 100 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H9NO2S
Molecular Weight: 171

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, reducing agents, acids, bases, acid chlorides.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 306937-38-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-(2,5-Dimethyl-1,3-thiazol-4-yl)acetic acid - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 306937-38-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 306937-38-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 306937-38-2 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

点击查看最新优质反应信息

文献信息

  • MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS
    申请人:Combs Andrew Paul
    公开号:US20090286778A1
    公开(公告)日:2009-11-19
    The present invention relates to macrocyclic compounds of Formula I: or pharmaceutically acceptable salts thereof or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are JAK/ALK inhibitors useful in the treatment of JAK/ALK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.
    本发明涉及以下化学式I的大环化合物: 或其药用可接受盐或季铵盐,其中所述成员在此提供,并且它们的组成物和使用方法,这些JAK/ALK抑制剂在治疗JAK/ALK相关疾病中有用,例如炎症和自身免疫性疾病以及癌症。
  • [EN] INDANONE AND INDANDIONE DERIVATIVES AND HETEROCYCLIC ANALOGS<br/>[FR] DÉRIVÉS D'INDANONE ET D'INDANEDIONE ET ANALOGUES HÉTÉROCYCLIQUES
    申请人:ACTELION PHARMACEUTICALS LTD
    公开号:WO2013068785A1
    公开(公告)日:2013-05-16
    The invention relates to indanone/indandione derivatives and heterocyclic analogs of Formula (I) wherein Ar1, A, B, L1, Y, Z, and (R1)n n are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments, especially as NPS receptor antagonists.
    这项发明涉及吲哚酮/吲哚二酮衍生物和式(I)中的杂环类似物,其中Ar1、A、B、L1、Y、Z和(R1)n n如描述中所述;其药学上可接受的盐,以及将这些化合物用作药物,特别是作为NPS受体拮抗剂。
  • 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES
    申请人:Aissaoui Hamed
    公开号:US20100016401A1
    公开(公告)日:2010-01-21
    The invention relates to 3-aza-bicyclo[3.1.0]hexane derivatives of formula (I) wherein A, B, n, X, and R 1 are as described in the description, and salts thereof, and their use as orexin receptor antagonists.
    这项发明涉及式(I)的3-aza-双环[3.1.0]己烷衍生物,其中A、B、n、X和R1如描述中所述,以及其盐,以及它们作为促进睡眠的荷尔蒙受体拮抗剂的用途。
  • [EN] USE OF DERIVATIVES OF 2, 4-DIHYDRO-[1,2,4]TRIAZOLE-3-THIONE AS INHIBITORS O FTEH ENZYME MYELOPEROXIDASE (MPO)<br/>[FR] UTILISATION DE DERIVES DE 2, 4-DIHYDRO-[1,2,4]TRIAZOLE-3-THIONES COMME INHIBITEURS DE L'ENZYME MYELOPEROXYDASE (MPO)
    申请人:ASTRAZENECA AB
    公开号:WO2004096781A1
    公开(公告)日:2004-11-11
    There is disclosed the use of a compound of formula (I) wherein X, Y, W and Q are as defined in the specification, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of the enzyme myeloperoxidase (MPO) is beneficial. Certain novel compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed, together with processes for their preparation. The compounds of formulae (I) are MPO inhibitors and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders.
    揭示了使用公式(I)中X、Y、W和Q如规范中定义的化合物及其药用盐,在制造药物中用于治疗或预防对髓过氧化物酶(MPO)抑制有益的疾病或症状。公开了某些公式(I)的新化合物及其药用盐,以及它们的制备方法。公式(I)的化合物是MPO抑制剂,因此在治疗或预防神经炎症性疾病中特别有用。
  • [EN] BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS<br/>[FR] DÉRIVÉS DE SPIRO[2.4]HEPTANE PONTÉS UTILES EN TANT QU'AGONISTES DU RÉCEPTEUR DE ALX ET/OU DU RÉCEPTEUR FPRL2
    申请人:ACTELION PHARMACEUTICALS LTD
    公开号:WO2010134014A1
    公开(公告)日:2010-11-25
    The present invention relates to bridged spiro[2.4]heptane derivatives of formula (I), wherein W, Y, Z, R1 and R2 are as defined in the description, their preparation and their use as pharmaceutically active compounds as ALX receptor and/or FPRL2 agonists for the treatment of inflammatory and obstructive airways diseases.
    本发明涉及桥式螺[2.4]庚烷衍生物的化学式(I),其中W、Y、Z、R1和R2如描述中所定义,它们的制备及其作为药用活性化合物的ALX受体和/或FPRL2激动剂在治疗炎症性和梗阻性气道疾病中的用途。
查看更多

同类化合物

伊莫拉明 (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5-氨基-1,3,4-噻二唑-2-基)甲醇 齐墩果-2,12-二烯[2,3-d]异恶唑-28-酸 黄曲霉毒素H1 高效液相卡套柱 非昔硝唑 非布索坦杂质Z19 非布索坦杂质T 非布索坦杂质K 非布索坦杂质E 非布索坦杂质67 非布索坦杂质65 非布索坦杂质64 非布索坦杂质61 非布索坦代谢物67M-4 非布索坦代谢物67M-2 非布索坦代谢物 67M-1 非布索坦-D9 非布索坦 非唑拉明 雷西纳德杂质H 雷西纳德 阿西司特 阿莫奈韦 阿米苯唑 阿米特罗13C2,15N2 阿瑞匹坦杂质 阿格列扎 阿扎司特 阿尔吡登 阿塔鲁伦中间体 阿培利司N-1 阿哌沙班杂质26 阿哌沙班杂质15 阿可替尼 阿作莫兰 阿佐塞米 镁(2+)(Z)-4'-羟基-3'-甲氧基肉桂酸酯 锌1,2-二甲基咪唑二氯化物 铵2-(4-氯苯基)苯并恶唑-5-丙酸盐 铬酸钠[-氯-3-[(5-二氢-3-甲基-5-氧代-1-苯基-1H-吡唑-4-基)偶氮]-2-羟基苯磺酸基][4-[(3,5-二氯-2-羟基苯 铁(2+)乙二酸酯-3-甲氧基苯胺(1:1:2) 钠5-苯基-4,5-二氢吡唑-1-羧酸酯 钠3-[2-(2-壬基-4,5-二氢-1H-咪唑-1-基)乙氧基]丙酸酯 钠3-(2H-苯并三唑-2-基)-5-仲-丁基-4-羟基苯磺酸酯 钠(2R,4aR,6R,7R,7aS)-6-(2-溴-9-氧代-6-苯基-4,9-二氢-3H-咪唑并[1,2-a]嘌呤-3-基)-7-羟基四氢-4H-呋喃并[3,2-D][1,3,2]二氧杂环己膦烷e-2-硫醇2-氧化物 野麦枯 野燕枯 醋甲唑胺